What does SARDAPHARMA do?

SARDAPHARMA is a pharmacy in Brussel. Private Limited, started on 14 November 2000, 1 establishment.

What is the address of SARDAPHARMA?

The registered office of SARDAPHARMA is located at Finisterraestraat 24, 1000 Brussel.

Is SARDAPHARMA still active?

Yes. According to the CBE (2 October 2026) SARDAPHARMA is active, legal situation “Normale toestand”, started on 14 November 2000.

Is SARDAPHARMA registered on Peppol?

Yes, SARDAPHARMA is registered on the Peppol network with ID 0208:0473270324.

What is the enterprise number of SARDAPHARMA?

The enterprise number of SARDAPHARMA is BE0473270324.

When was SARDAPHARMA founded?

SARDAPHARMA was founded on 14 November 2000.

Is SARDAPHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 14 November 2000; 4 annual accounts filed, latest fiscal year 2024.

How much profit did SARDAPHARMA make in 2024?

SARDAPHARMA posted a profit after taxes of € 22,250 in financial year 2024.

What is the revenue of SARDAPHARMA?

As a small company, SARDAPHARMA is not required to publish revenue in its annual accounts. In financial year 2024, its added value was € 178,450.

SARDAPHARMA (Private Limited) - Brussel - BE0473270324

Dossier SARDAPHARMA, printed on 2 October 2026 from databakkes.be/en/0473270324/sardapharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2024

SARDAPHARMA from Brussel, company number BE0473270324, closed financial year 2024 with a result of € 22,250 after tax. For that financial year SARDAPHARMA recorded a gross margin of € 178,450 and equity of € 237,664. Compared with financial year 2023, the result moved from € 8,134 to € 22,250. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on November 14, 2025.

What it is worth Growing

€ 237,664

▲ 10% vs 2023

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 22,250

▲ 174% vs 2023

Profit after tax over the fiscal year.

Cash in the bank

€ 39

▼ 99% vs 2023

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2024. Retained profit grew to € 219,072.

People and assets in 2024

Wage cost

€ 46,734

▼ 17% vs 2023

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 9,772

▲ 8% vs 2023

Book value of vehicles, furniture and equipment.

Debts at end 2024

Bank debt ≈ 14 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 599,335

▲ 1% vs 2023

€ 41,125 is repaid this year. At this pace the long-term loan is gone in ≈ 14 years.

Owed to suppliers

€ 106,759

▼ 36% vs 2023

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 11,435

▼ 30% vs 2023

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2021	2022	2023	2024	Change 2023 → 2024
Gross margin	€ 143,025 Gross margin 2021: € 143,025 First fiscal year in the series	€ 166,247 Gross margin 2022: € 166,247 ▲ 16% vs 2021 (€ 143,025) Favourable step	€ 198,401 Gross margin 2023: € 198,401 ▲ 19% vs 2022 (€ 166,247) Favourable step	€ 178,450 Gross margin 2024: € 178,450 ▼ 10% vs 2023 (€ 198,401) Unfavourable step	▼ 10%
Profit after taxes	€ 100,665 Profit after taxes 2021: € 100,665 First fiscal year in the series	€ 12,273 Profit after taxes 2022: € 12,273 ▼ 88% vs 2021 (€ 100,665) Unfavourable step	€ 8,134 Profit after taxes 2023: € 8,134 ▼ 34% vs 2022 (€ 12,273) Unfavourable step	€ 22,250 Profit after taxes 2024: € 22,250 ▲ 174% vs 2023 (€ 8,134) Favourable step	▲ 174%
Equity	€ 195,008 Equity 2021: € 195,008 First fiscal year in the series	€ 207,280 Equity 2022: € 207,280 ▲ 6% vs 2021 (€ 195,008) Favourable step	€ 215,415 Equity 2023: € 215,415 ▲ 4% vs 2022 (€ 207,280) Favourable step	€ 237,664 Equity 2024: € 237,664 ▲ 10% vs 2023 (€ 215,415) Favourable step	▲ 10%
Total debts	€ 878,195 Total debts 2021: € 878,195 First fiscal year in the series	€ 739,819 Total debts 2022: € 739,819 ▼ 16% vs 2021 (€ 878,195) Favourable step	€ 784,881 Total debts 2023: € 784,881 ▲ 6% vs 2022 (€ 739,819) Unfavourable step	€ 717,529 Total debts 2024: € 717,529 ▼ 9% vs 2023 (€ 784,881) Favourable step	▼ 9%
Cash	€ 4,569 Cash 2021: € 4,569 First fiscal year in the series	€ 7,876 Cash 2022: € 7,876 ▲ 72% vs 2021 (€ 4,569) Favourable step	€ 4,951 Cash 2023: € 4,951 ▼ 37% vs 2022 (€ 7,876) Unfavourable step	€ 39 Cash 2024: € 39 ▼ 99% vs 2023 (€ 4,951) Unfavourable step	▼ 99%
Land & buildings	€ 385,147 Land & buildings 2021: € 385,147 First fiscal year in the series	€ 362,624 Land & buildings 2022: € 362,624 ▼ 6% vs 2021 (€ 385,147) Unchanged	€ 340,100 Land & buildings 2023: € 340,100 ▼ 6% vs 2022 (€ 362,624) Unchanged	€ 319,601 Land & buildings 2024: € 319,601 ▼ 6% vs 2023 (€ 340,100) Unchanged	▼ 6%
Retained profit	€ 176,416 Retained profit 2021: € 176,416 First fiscal year in the series	€ 188,688 Retained profit 2022: € 188,688 ▲ 7% vs 2021 (€ 176,416) Favourable step	€ 196,823 Retained profit 2023: € 196,823 ▲ 4% vs 2022 (€ 188,688) Favourable step	€ 219,072 Retained profit 2024: € 219,072 ▲ 11% vs 2023 (€ 196,823) Favourable step	▲ 11%
Bank debt	€ 630,335 Bank debt 2021: € 630,335 First fiscal year in the series	€ 639,653 Bank debt 2022: € 639,653 ▲ 1% vs 2021 (€ 630,335) Unfavourable step	€ 595,276 Bank debt 2023: € 595,276 ▼ 7% vs 2022 (€ 639,653) Favourable step	€ 599,335 Bank debt 2024: € 599,335 ▲ 1% vs 2023 (€ 595,276) Unfavourable step	▲ 1%
Balance sheet total	€ 1,073,203 Balance sheet total 2021: € 1,073,203 First fiscal year in the series	€ 947,099 Balance sheet total 2022: € 947,099 ▼ 12% vs 2021 (€ 1,073,203) Unchanged	€ 1,000,296 Balance sheet total 2023: € 1,000,296 ▲ 6% vs 2022 (€ 947,099) Unchanged	€ 955,194 Balance sheet total 2024: € 955,194 ▼ 5% vs 2023 (€ 1,000,296) Unchanged	▼ 5%
Employees (FTE)	-	-	0.9 Employees (FTE) 2023: 0.9 First fiscal year in the series	-

Key figures of SARDAPHARMA, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.

What happened to SARDAPHARMA?

What happened at SARDAPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Nov 14, 2025 New annual accounts for financial year 2024: profit of € 22,250 (▲ 174% vs 2023). filed late Source: NBB ↗
Nov 22, 2000 New establishment in Brussel. KBO
Nov 14, 2000 Start of the company according to the CBE. KBO

In short

From € 100,665 profit in 2021 to € 22,250 profit in 2024.

Paid € 27,031 in corporate taxes since 2021.

Best year ever: 2021, with € 100,665 profit.

Original PDFs at the National Bank ↗

A new publication or filing at SARDAPHARMA? We notify you, reason included.

Follow SARDAPHARMA

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Establishments

Establishment units

Physical locations of this company

Registered office

Finisterraestraat 24

1000 Brussel

2.096.826.828

Finisterraestraat 22-24

1000 Brussel

Active since 22 November 2000

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

PHARMA RUE NEUVE

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0473.270.324
VAT number: BE 0473.270.324
Registered office: Finisterraestraat 24, 1000 Brussel
Names & denominations: SARDAPHARMA
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 14 November 2000
Peppol: Active · Active since 13 Oct 2025
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗

SARDAPHARMA